Pure Global
NCT06416436

Dose-escalation Study of Ultra-high Dose Ablative Radiosurgery With Immunotherapy for Bulky Metastatic Cancer Patients

Immunotherapy in Combination With Ablative Radiosurgery to Ultra-high DoSes (ICARUS): A Phase I Dose-escalation Radiosurgery Study in Metastatic Cancers
University of Kansas Medical Center·Phase 1·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Solid Tumor
Drug/Device/Intervention
Atezolizumab
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
University of Kansas Medical Center
Location
Kansas City, United States of America
Timeline & enrollment
Phase
Phase 1
Start date
May 23, 2024
End date
Jul 01, 2027
Enrollment
54 participants
Primary outcome

Maximum tolerated dose of ultra-high dose Stereotactic Ablative Radiotherapy (SBRT) for 3 different body sites

Summary

The purpose of this study is to determine whether cytoreduction of bulky metastatic disease
 using ultra high dose SBRT in combination with immunotherapy is tolerable and feasible In
 patients who have exhausted SoC treatment options.

ICD-10 classifications
Malignant neoplasm: Connective and soft tissue, unspecifiedCarcinoma in situ, unspecifiedMalignant neoplasm: ParametriumMalignant neoplasm of other connective and soft tissueMalignant neoplasm: Lip, unspecified, inner aspect
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06416436
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06416436 through Pure Global AI's free database. This Phase 1 trial is sponsored by University of Kansas Medical Center and is currently Not yet recruiting. The study focuses on Solid Tumor. Target enrollment is 54 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.